Platelet activity of high-dose factor VIIa is independent of tissue factor

British Journal of Haematology

Volumn 99, Issue 3, 1997, Pages 542-547

  Monroe, Dougald M ^a   Hoffman, Maureane ^b   Oliver, Julie A ^b   Roberts, Harold R ^b  

^a Division of Hematology/Oncology   (United States)

^b NONE

Author keywords

Factor VII; Factor X; Haemostasis; Platelet; Thrombin

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8 CONCENTRATE; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HEMOPHILIA; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE ACTIVATION;

EID: 0030695063     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.4463256.x     Document Type: Article

References (26)

1. 2+, phospholipids and tissue-factor apoprotein to the activation of human blood coagulation factor X by activated factor VII. Biochemical Journal, 265, 327-336.
2. Church, F.C., Pratt, C.W., Treanor, R.E. & Whina, H.C. (1988) Antithrombin action of phosvitin and other phosphate-containing polyanions is mediated by heparin cofactor II. FEBS Letters, 237, 26-30.
3. Diness, V., Bregengaard, C., Erhardtsen, E. & Hedner, U. (1992) Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thrombosis Research, 67, 233-241.
4. Drake, T.A., Morrissey, J.H. & Edgington, T.S. (1989) Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. American Journal of Pathology, 134, 1087-1097.
5. Hedner, U., Glazer, S. & Falch, J. (1993) Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfusion Medicine Reviews, 7, 78-83.
6. Hedner, U., Glazer, S., Pingel, K., Alberts, K.A., Blombäck, M., Schulman, S. & Johnsson, H. (1988) Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet, ii, 1193.
7. Hoffman, M., Monroe, D.M., Oliver, J.A. & Roberts, H.R. (1995) Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 86, 1794-1801.
8. Hoffman, M., Monroe, D.M. & Roberts, H.R. (1992a) Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thrombosis and Haemostasis, 68, 74-78.
9. Hoffman, M., Monroe, D.M. & Roberts, H.R. (1992b) A rapid method for isolation of platelets from human blood by density gradient centrifugation. American Journal of Clinical Pathology, 98, 531-533.
10. Hoffman, M., Monroe, D.M. & Roberts, H.R. (1994) Human monocytes support factor X activation by factor VIIa independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood, 83, 38-42.
11. Hung, D.T., Vu, T.K., Wheaton, V.I., Ishii, K. & Coughlin, S.R. (1992) Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. Journal of Clinical Investigation, 89, 1350-1353.
12. Jones, M.E., Griffith, M.J., Monroe, D.M., Roberts, H.R. & Lentz, B.R. (1985) Comparison of lipid-binding and kinetic properties of normal, variant, and Gla-modified human factor IX and IXa. Biochemistry, 24, 8064-8069.
13. Kristensen, J., Killander, A., Hippe, E., Helleberg, C., Ellegård, J., Holm, M., Kutti, J., Mellqvist, U.-H., Johansson, J.E., Glazer, S. & Hedner, U. (1996) Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Hemostasis, 26, (Suppl. 1), 159-165.
14. Lindley, C.M., Sawyer, W.T., Macik, B.G., Lusher, J., Harrison, J.F., Baird-Cox, K., Birch, K., Glazer, S. & Roberts, H.R. (1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clinical Pharmacology and Therapeutics, 55, 638-648.
15. Macik, B.G., Hohneker, J., Roberts, H.R. & Griffin, A.M. (1989) Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. American Journal of Hematology, 362, 232-234.
16. Macik, B.G., Lindley, C.M., Lusher, J., Sawyer, W.T., Bloom, A.L., Harrison, J.F., Baird-Cox, K., Birch, K., Glazer, S. & Roberts, H.R. (1993) Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coagulation and Fibrinolysis, 4, 521-527.
17. McCord, D.M., Monroe, D.M., Smith, K.J. & Roberts, H.R. (1940) Characterization of the functional defect in factor IX Alabama: evidence for a conformational change due to high-affinity calcium binding in the first epidermal growth factor domain. Journal of Biological Chemistry, 265, 10250-10254.
18. O'Marcaigh, A.S., Schmalz, B.J., Shaughnessy, W.J. & Gilchrist, G.S. (1994) Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clinic Proceedings, 69, 641-644.
19. Rao, L.V. & Rapaport, S.I. (1990) Factor VIIa catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood, 75, 1069-1073.
20. Rao, L.V.M., Williams, T. & Rapaport, S.I. (1996) Studies on the activation of factor VII bound to tissue factor. Blood, 87, 3738-3748.
21. Schmidt, M.L., Gamerman, S., Smith, H.E., Scott, J.P. & DiMichele, D.M. (1994) Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. American Journal of Hematology, 47, 36-40.
22. Smith, O.P. & Hann, I.M. (1996) rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. British Journal of Hematology, 92, 1002-1004.
23. Sumner, W.T., Monroe, D.M. & Hoffman, M. (1996) Variability in platelet procoagulant activity in healthy volunteers. Thrombosis Research, 81, 533-543.
24. Telgt, D.S.C., Macik, B.G., McCord, D.M., Monroe, D.M. & Roberts, H.R. (1989) Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thrombosis Research, 56, 603-609.
25. ten Cate, H., Bauer, K.A., Levi, M., Edgington, T.S., Sublett, R.D., Barzegar, S., Kass, B.L. & Rosenberg, R.D. (1993) The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. Journal of Clinical Investigation, 92, 1207-1212.
26. Yan, S.C.B., Pazzano, P., Chao, Y.B., Walls, J.D., Berg, D.T., McClure, D.B. & Grinnell, B.W. (1990) Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Bio/Technology, 8, 655-661.